Clearing the Air on Residual Solvents - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Clearing the Air on Residual Solvents
USP 9467: Residual Solvents will take effect on July 1, 2008. But does the industry understand these specifications—and is it prepared?

Pharmaceutical Technology

The i's have been dotted, and the t's have been crossed. After years of revisions, debates, and delays, the USP General Chapter 467 Residual Solvents will finally take effect on July 1, 2008. Although most large, multinational pharmaceutical companies have been preparing for these requirements for some time, there is still a significant portion of the industry, especially smaller firms, that are either not aware of how USP ‹467› will change their analytical practices or are in denial that the standards will directly affect them.

Many raw materials used to manufacture pharmaceutical products contain residual solvents at various levels. Because USP ‹467› applies to all compendial drug substances, excipients, and products, this chapter influences all aspects of the industry. Despite the preparation and even after several workshops and conferences on the topic, confusion and questions remain about where the solvent limits actually apply, how the methods should be established, when the data should be reported, and what information is required from ingredient suppliers. To help answer these questions, industry experts and regulators are collectively encouraging analysts to pay attention to the details in the chapter.

Background and application

The new USP ‹467› chapter replaces the previous ‹467› "Organic Volatile Impurities" (OVI) chapter established in 1990. Although the OVI chapter specified several methods for monitoring seven highly toxic solvents, it omitted many other industry solvents. Moreover, the methods were based on direct-injection gas chromatography (GC). In direct injection, the GC autosampler needle dips into the liquid, takes up liquid, and shoots the solution onto the GC. "This technique is hard on the GC because you are injecting not only the volatiles but also the API, which is typically not volatile. That is the way it was done because there simply wasn't a better way to reliably sample for these volatile impurities," says Jon Brice, PhD, director of pharmaceutical services at BioScreen Testing Services (Torrance, CA). "Ultimately it wasn't very effective," agrees Neil Schwarzwalder, global compendial consultant, Global Quality Laboratories, at Eli Lilly and Company (Indianapolis, IN).

In 1997, the International Conference on Harmonization (ICH) published Q3C, "Impurities: Guideline for Residual Solvents," which provides guidance for 59 residual solvents. Before the US Food and Drug Administration approved the ICH guideline in 1997, manufacturers had only the OVI general chapter to go by, and there was no general guideline on residual solvents. At that time, manufacturers conducted their own toxicology assessments of the solvents that they used for new products. The ICH guideline was uniform, and manufacturers had a standard that they could meet for new products. It did not apply to existing products, however. "The industry was in a situation where they were applying one standard to the new materials, another standard for older materials, and perhaps for really old products, no standard," says Schwarzwalder.

For harmonization, the new USP ‹467› chapter is patterned closely after the ICH Q3C guideline. The latest revision was published in December 2007 and was meant to correct the final points of disagreement. "USP, the industry, and FDA have worked very hard to resolve those differences," says Larry Ouderkirk, director of Compendial Operations Staff at FDA/CDER/OPS-IO. " I believe now what we've got in the latest version of ‹467› is something that is virtually identical to Q3C. I don't think there's any substantive differences left that haven't been addressed, and I think industry is now satisfied that the differences have been resolved."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here